[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-oric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data-IT":150},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[],{"post":151,"seo":187,"relatedPosts":195,"suggestedPosts":274},{"id":152,"title":153,"date":154,"modified":155,"excerpt":156,"content":157,"wordCount":158,"lang":159,"uri":160,"slug":161,"cloudinaryAssetId":162,"featuredImageOriginalUrl":163,"featuredImageMetadata":164,"author":167,"editor":173,"categories":178,"relatedPosts":184,"seo":185},145819,"ORIC Pharmaceuticals Crolla del 22% Mentre J&J Presenta Dati Rivali sul Cancro alla Prostata","2026-10-26T16:39:42","2026-10-26T16:39:48","\u003Cp>Le buone notizie di venerdì non sono durate a lungo\u003C\u002Fp>","\u003Ch2 id=\"h-key-takeaways\" class=\"wp-block-heading\">Punti Chiave\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>Le azioni di ORIC Pharmaceuticals sono scese del 22% oggi dopo che Johnson & Johnson ha presentato dati preliminari per JNJ-6143, un farmaco rivale per il cancro alla prostata.\u003C\u002Fli>\n\n\n\n\u003Cli>Il calo sembra eccessivo, dato che i dati di J&J provengono da un piccolo studio in fase iniziale e il farmaco per il cancro alla prostata di ORIC è già in uno studio di Fase 3.\u003C\u002Fli>\n\n\n\n\u003Cli>Alla dose di 50 mg, il farmaco di J&J ha prodotto un tasso di risposta del 75% in 16 pazienti con malattia misurabile, e quei pazienti avevano già ricevuto una mediana di quattro trattamenti precedenti.\u003C\u002Fli>\n\n\n\n\u003Cli>ORIC ha 388 milioni di dollari in cassa e investimenti e prevede che bastino fino alla seconda metà del 2028, oltre il risultato principale del suo studio di Fase 3.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>ORIC Pharmaceuticals (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=303713108&tid=656973915\">ORIC\u003C\u002Fa>)\u003C\u002Fstrong> è in calo del 22% oggi, e la cattiva notizia non è nemmeno sua. Durante il fine settimana, \u003Cstrong>Johnson & Johnson (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=139677&tid=2623227\">JNJ\u003C\u002Fa>)\u003C\u002Fstrong> ha presentato dati preliminari sul suo farmaco sperimentale per il cancro alla prostata, JNJ-6143. Gli investitori lo hanno interpretato come una minaccia diretta al farmaco principale di ORIC, il rinzimetostat.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-j-amp-j-s-immaculate-numbers\" class=\"wp-block-heading\">I numeri \"immacolati\" di J&J\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Al Congresso ESMO di sabato, J&J ha \u003Ca href=\"https:\u002F\u002Fwww.morningstar.com\u002Fnews\u002Fpr-newswire\u002F20261025ny80315\u002Fjohnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule\">riportato i risultati della Fase 1\u003C\u002Fa> in uomini con cancro alla prostata avanzato che avevano ricevuto una mediana di quattro trattamenti precedenti. Alla dose di 50 mg, il 75% dei pazienti con malattia misurabile (12 su 16) ha avuto una risposta completa o parziale confermata. E il 77% di 38 pazienti ha visto il proprio PSA diminuire almeno della metà.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">L'analista di Leerink Asthika Goonewardene ha definito i dati \"immacolati\" e ha affermato che i risultati \"aumentano il potenziale livello di minaccia\" per il rinzimetostat.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>TIKR monitora 15 analisti su ORIC Pharmaceuticals. Quanti dicono \"Compra\"?\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Vedi la suddivisione completa dei rating Compra, Mantieni e Vendi su ORIC Pharmaceuticals, insieme alle stime di ricavi e utili di Wall Street, tutto in un unico posto. Più di 500.000 investitori utilizzano TIKR per ricercare titoli come questo. \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">Vedi i Rating degli Analisti per ORIC Pharmaceuticals\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-a-lot-rides-on-rinzimetostat\" class=\"wp-block-heading\">Molto dipende dal rinzimetostat\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Il rinzimetostat è il farmaco più avanzato di ORIC. A luglio, ORIC ha \u003Ca href=\"https:\u002F\u002Fwww.biospace.com\u002Fpress-releases\u002Foric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with-bayer\">avviato Himalayas-1\u003C\u002Fa>. È uno studio di Fase 3 che abbina il rinzimetostat al darolutamide di Bayer in uomini il cui cancro alla prostata si è diffuso e continua a crescere dopo l'abiraterone, un trattamento ormonale standard.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">I pazienti di J&J avevano ricevuto più trattamenti. Ma se JNJ-6143 regge, mi aspetto che J&J lo spinga verso pazienti in stadi precedenti, proprio dove si sta dirigendo il rinzimetostat.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">ORIC aveva 265 milioni di dollari di cassa e investimenti a breve termine al 30 giugno...\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA\" alt=\"Bar chart from TIKR of ORIC Pharmaceuticals' cash and short-term investments, $ millions, last 8 quarters (to June 30, 2026).\" class=\"wp-post-145819 wp-image-145817\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793030374\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793030374\u002Fimages\u002FORIC-2026-10-26_ORIC_cash_8q\u002FORIC-2026-10-26_ORIC_cash_8q.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">ORIC Pharmaceuticals (ORIC): cassa e investimenti a breve termine, milioni di dollari, ultimi 8 trimestri (al 30 giugno 2026) (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">...più 123 milioni di dollari in investimenti a lungo termine, per un totale di 388 milioni di dollari. La \u003Ca href=\"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F0001796280\u002F000119312526330568\u002Foric-ex99_1.htm\">direzione prevede\u003C\u002Fa> che bastino fino alla seconda metà del 2028, oltre il risultato principale di Himalayas-1.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Con un valore di mercato di circa 1,1 miliardi di dollari, ciò lascia ancora circa 700 milioni di dollari sulla pipeline, e il rinzimetostat ne è il pezzo più grande.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-the-lung-drug-is-still-there\" class=\"wp-block-heading\">Il farmaco per il cancro al polmone è ancora lì\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Venerdì, ORIC ha \u003Ca href=\"https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F10\u002F23\u002F3387076\u002F0\u002Fen\u002Foric-pharmaceuticals-presents-potential-best-in-class-data-for-enozertinib-in-1l-nsclc-patients-with-egfr-atypical-mutations-at-esmo-congress-2026-and-plans-to-advance-enozertinib-.html\">riportato un tasso di risposta confermato dell'84%\u003C\u002Fa> per l'enzertinib, il suo farmaco per il cancro al polmone, in 26 pazienti non trattati. Prevede di avviare uno studio di Fase 3 nella prima metà del 2027. Questa mattina, Stifel ha alzato il suo target price a 18 dollari da 14.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Il target price consenso degli analisti è salito nell'ultimo anno...\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA\" alt=\"Line chart from TIKR of ORIC Pharmaceuticals' analysts' consensus (mean) price target, $ per share, last year.\" class=\"wp-post-145819 wp-image-145818\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793030372\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793030372\u002Fimages\u002FORIC-2026-10-26_ORIC_street_targets_1yr\u002FORIC-2026-10-26_ORIC_street_targets_1yr.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">ORIC Pharmaceuticals (ORIC): target price consenso (media) degli analisti, dollari per azione, ultimo anno (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">...a circa 22 dollari, più del doppio rispetto al prezzo attuale del titolo.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">La mia opinione: i dati di J&J sono una minaccia reale, ma provengono da 16 pazienti in uno studio di Fase 1. ORIC ha uno studio di Fase 3 in corso, un secondo farmaco che si avvia verso uno, e la cassa per arrivare al risultato. Perdere [il 22%] su uno studio iniziale di un rivale mi sembra eccessivo.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Naturalmente, ORIC deve ancora fornire agli investitori un aggiornamento sul rinzimetostat quest'anno. Se quell'aggiornamento apparirà più debole rispetto ai numeri di J&J, la vendita sembrerà molto più ragionevole.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-so-what-is-oric-pharmaceuticals-stock-actually-worth\" class=\"wp-block-heading\">Quindi, qual è il valore effettivo del titolo ORIC Pharmaceuticals?\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">TIKR ti permette di prevedere il prezzo futuro di qualsiasi titolo in meno di un minuto. Basta inserire alcune ipotesi nel modello di valutazione di TIKR e vedere quanto potrebbe valere ORIC Pharmaceuticals. Parti dalle stime consenso di Wall Street, o modifica gli input per riflettere la tua visione del business. È gratuito.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">Valuta ORIC Pharmaceuticals gratuitamente\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch3 id=\"h-disclaimer\" class=\"wp-block-heading\">\u003Cstrong>Disclaimer:\u003C\u002Fstrong>\u003C\u002Fh3>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cem>Si prega di notare che gli articoli su TIKR non intendono costituire consulenza in materia di investimenti o finanziaria da parte di TIKR o del nostro team di contenuti, né sono raccomandazioni per acquistare o vendere titoli. Creiamo i nostri contenuti sulla base dei dati di investimento di TIKR Terminal e delle stime degli analisti. La nostra analisi potrebbe non includere notizie recenti o aggiornamenti importanti sulle società. TIKR non ha posizioni in nessuno dei titoli menzionati. Grazie per la lettura e buoni investimenti!\u003C\u002Fem>\u003C\u002Fp>",746,"it","\u002Fblog\u002Foric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data","oric-pharmaceuticals-sinks-22-as-jj-presents-rival-prostate-cancer-data","images\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793030373\u002Fimages\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d\u002Fpuzzled-man-with-a-tablet-falling-chart-and-trading-screens_14582053b8d.png?_i=AA",{"altText":165,"imageCredit":166},"ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data","MangoStar_Studio from Getty Images via Canva",{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":172},"Roxanna Maglangit","roxtikr","author","",[],{"name":174,"slug":175,"role":176,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":177},"Michael Douglass","MichaelDouglass","editor",[],[179],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},"Investimenti generali","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",0,[],{"title":165,"metaDesc":186,"opengraphDescription":186,"twitterTitle":165,"twitterDescription":186},"Friday’s good news didn’t last long",{"title":188,"description":189,"twitterTitle":188,"twitterDescription":189,"author":168,"articlePublisher":190,"articlePublishedTime":154,"articleModifiedTime":155,"twitterLabel1":191,"twitterData1":192,"ogTitle":188,"ogDescription":189,"ogUrl":160,"ogImage":163,"ogImageWidth":193,"ogImageHeight":194,"ogImageSecureUrl":163,"ogImageAlt":165,"twitterImage":163},"ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data","Friday’s good news didn’t last long","TIKR.com","Tempo di lettura stimato","6 minutes",1200,630,[196,212,227,244,259],{"id":183,"title":197,"date":198,"excerpt":199,"wordCount":200,"uri":201,"slug":202,"cloudinaryAssetId":203,"featuredImageOriginalUrl":204,"featuredImageMetadata":205,"author":206,"categories":209,"relatedPosts":211},"Tesla Balza del 6% dopo l'Upgrade di Barclays che Definisce la Fusione con SpaceX \"Parte Chiave del Caso Bull per Tesla\"","2026-10-26 16:28:00","Un piano di acquisizione è efficace solo quanto il sostegno che lo sostiene",716,"\u002Fblog\u002Ftesla-soars-6-on-barclays-upgrade-calling-spacex-merger-key-part-of-the-tesla-bull-case","tesla-soars-6-on-barclays-upgrade-calling-spacex-merger-key-part-of-the-tesla-bull-case","images\u002Felon-musk-onstage-spacex-falcon-9-launch\u002Felon-musk-onstage-spacex-falcon-9-launch","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793023734\u002Fimages\u002Felon-musk-onstage-spacex-falcon-9-launch\u002Felon-musk-onstage-spacex-falcon-9-launch.png?_i=AA",{"altText":197},{"name":174,"slug":207,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":208},"michaeldouglass",[],[210],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":213,"date":214,"excerpt":215,"wordCount":216,"uri":217,"slug":218,"cloudinaryAssetId":219,"featuredImageOriginalUrl":220,"featuredImageMetadata":221,"author":222,"categories":224,"relatedPosts":226},"Wall Street si aspetta che Tesla bruci 4 miliardi di dollari questo trimestre. Un anno fa ne generava 4 miliardi.","2026-10-26 16:21:00","Il numero di cassa di stasera mostra chi sta pagando per i robot",861,"\u002Fblog\u002Fwall-street-expects-tesla-to-burn-4-billion-this-quarter-a-year-ago-it-generated-4-billion","wall-street-expects-tesla-to-burn-4-billion-this-quarter-a-year-ago-it-generated-4-billion","images\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792699327\u002Fimages\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva\u002FTSLA-stock-U-S-Air-Force-photo-by-Trevor-Cokley-and-Bl-ke-from-Pexels-via-Canva.png?_i=AA",{"altText":213},{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":223},[],[225],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":228,"date":229,"excerpt":230,"wordCount":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":237,"categories":241,"relatedPosts":243},"Intel guadagna il 4% dopo l'upgrade di New Street, con la carenza di CPU per server destinata a \"persistere per anni\"","2026-10-26 16:01:15","Una chiamata audace, tre giorni prima della grande prova di Intel",701,"\u002Fblog\u002Fintel-gains-4-on-new-street-upgrade-as-server-cpu-crunch-is-set-to-persist-for-years","intel-gains-4-on-new-street-upgrade-as-server-cpu-crunch-is-set-to-persist-for-years","images\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792699318\u002Fimages\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva\u002FMETA-stock-Dean-Drobot-and-Nikada-from-Getty-Images-Signature-via-Canva.png?_i=AA",{"altText":228},{"name":238,"slug":239,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":240},"David Hanson","davidtikr",[],[242],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":245,"date":246,"excerpt":247,"wordCount":248,"uri":249,"slug":250,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":251,"author":252,"categories":256,"relatedPosts":258},"Bill Gates: Meta's Musa È \"il Primo Vero Grande Prodotto di IA per i Consumatori\"","2026-10-26 15:52:36","Grandi elogi, e ora l'orologio corre",1067,"\u002Fblog\u002Fbill-gates-metas-muse-is-the-first-truly-great-consumer-ai-product","bill-gates-metas-muse-is-the-first-truly-great-consumer-ai-product",{"altText":245},{"name":253,"slug":254,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":255},"Bobby Sankhagowit","bobby",[],[257],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":260,"date":261,"excerpt":262,"wordCount":263,"uri":264,"slug":265,"cloudinaryAssetId":266,"featuredImageOriginalUrl":267,"featuredImageMetadata":268,"author":269,"categories":271,"relatedPosts":273},"Nvidia potrebbe sfruttare una \"completamente legale\" scappatoia in Cina che vale miliardi. Ma (probabilmente) non lo farà.","2026-10-26 15:50:14","Ha cose migliori da fare con i suoi chip.",988,"\u002Fblog\u002Fnvidia-could-exploit-completely-legal-china-loophole-worth-billions-but-it-probably-wont","nvidia-could-exploit-completely-legal-china-loophole-worth-billions-but-it-probably-wont","images\u002Fdoubtful-man-with-glasses-in-hand-data-center\u002Fdoubtful-man-with-glasses-in-hand-data-center","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793027299\u002Fimages\u002Fdoubtful-man-with-glasses-in-hand-data-center\u002Fdoubtful-man-with-glasses-in-hand-data-center.png?_i=AA",{"altText":260},{"name":174,"slug":207,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":270},[],[272],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],[275,295,310,324,339,359,374,389,404],{"id":183,"title":276,"date":277,"excerpt":278,"wordCount":279,"uri":280,"slug":281,"cloudinaryAssetId":282,"featuredImageOriginalUrl":283,"featuredImageMetadata":284,"author":285,"categories":289,"relatedPosts":294},"In rialzo del 13% negli ultimi 12 mesi, le azioni di Arista Networks possono offrire rendimenti migliori nel 2026?","2026-10-26 12:57:00","Il titolo di Arista è salito del 10% in un anno. Scopri cosa dice il Modello di Valutazione di TIKR sul potenziale rialzista di ANET, con un prezzo obiettivo di $275 entro dicembre 2028.",1099,"\u002Fblog\u002Farista-networks-stock-valuation-anet-2026","arista-networks-stock-valuation-anet-2026","images\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793010558\u002Fimages\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva.png?_i=AA",{"altText":276},{"name":286,"slug":287,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":288},"Aditya Raghunath","adityatikr",[],[290],{"name":291,"slug":292,"uri":293,"description":171,"postsCount":183},"Valutazione","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":183,"title":296,"date":297,"excerpt":298,"wordCount":299,"uri":300,"slug":301,"cloudinaryAssetId":302,"featuredImageOriginalUrl":303,"featuredImageMetadata":304,"author":305,"categories":307,"relatedPosts":309},"In calo del 48% negli ultimi 12 mesi, le azioni SoFi possono offrire risultati migliori nel 2026?","2026-10-26 12:45:00","Il titolo SoFi è sceso del 51% in un anno. Scopri cosa dice il Modello di Valutazione di TIKR sul potenziale rialzista di SOFI, con un prezzo obiettivo di $22 entro dicembre 2028.",1081,"\u002Fblog\u002Fsofi-stock-valuation-sofi-2026","sofi-stock-valuation-sofi-2026","images\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793015325\u002Fimages\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva.png?_i=AA",{"altText":296},{"name":286,"slug":287,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":306},[],[308],{"name":291,"slug":292,"uri":293,"description":171,"postsCount":183},[],{"id":183,"title":311,"date":297,"excerpt":312,"wordCount":313,"uri":314,"slug":315,"cloudinaryAssetId":316,"featuredImageOriginalUrl":317,"featuredImageMetadata":318,"author":319,"categories":321,"relatedPosts":323},"Aumentando Solo del 9% negli Ultimi 12 Mesi, le Azioni Palantir Possono Offrire Rendimenti Migliori nel 2026?","Il titolo Palantir è salito solo del 4% in un anno. Scopri cosa dice il Modello di Valutazione di TIKR sul potenziale rialzista di PLTR, con un obiettivo di $529 entro dicembre 2028.",1024,"\u002Fblog\u002Fpalantir-stock-valuation-pltr-2026","palantir-stock-valuation-pltr-2026","images\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793003212\u002Fimages\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c.png?_i=AA",{"altText":311},{"name":286,"slug":287,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":320},[],[322],{"name":291,"slug":292,"uri":293,"description":171,"postsCount":183},[],{"id":183,"title":325,"date":326,"excerpt":327,"wordCount":328,"uri":329,"slug":330,"cloudinaryAssetId":331,"featuredImageOriginalUrl":332,"featuredImageMetadata":333,"author":334,"categories":336,"relatedPosts":338},"Sceso del 56% negli ultimi 12 mesi, il titolo AppLovin può offrire rendimenti migliori nel 2026?","2026-10-26 12:33:00","Il titolo AppLovin è sceso del 60% in un anno. Scopri cosa dice il Modello di Valutazione di TIKR sul potenziale rialzista di APP, con un prezzo obiettivo di $366 entro dicembre 2028.",1139,"\u002Fblog\u002Fapplovin-stock-valuation-app-2026","applovin-stock-valuation-app-2026","images\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793013215\u002Fimages\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2.png?_i=AA",{"altText":325},{"name":286,"slug":287,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":335},[],[337],{"name":291,"slug":292,"uri":293,"description":171,"postsCount":183},[],{"id":183,"title":340,"date":341,"excerpt":342,"wordCount":343,"uri":344,"slug":345,"cloudinaryAssetId":346,"featuredImageOriginalUrl":347,"featuredImageMetadata":348,"author":349,"categories":353,"relatedPosts":358},"Il titolo ExxonMobil ha chiuso a un massimo storico mentre il Brent superava i 116 dollari. Ecco dove potrebbe arrivare il titolo entro il 2030","2026-10-26 07:55:00","ExxonMobil ha chiuso a un record di $183,21 il 23 ottobre mentre il Brent superava i $116, e ora si scambia al di sopra del target medio degli analisti. Il suo CFO afferma che le sinergie con Pioneer sono raddoppiate e Exxon punta a raddoppiare il recupero nel Permiano con meno pozzi, un fattore di costo che l'azienda controlla.",791,"\u002Fblog\u002Fexxonmobil-stock-hit-a-record-close-as-brent-topped-116-heres-where-the-stock-could-go-by-2030","exxonmobil-stock-hit-a-record-close-as-brent-topped-116-heres-where-the-stock-could-go-by-2030","images\u002F13-10\u002F13-10","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976181\u002Fimages\u002F13-10\u002F13-10.png?_i=AA",{"altText":340},{"name":350,"slug":351,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":352},"Wiltone Asuncion","wiltonetikr",[],[354],{"name":355,"slug":356,"uri":357,"description":171,"postsCount":183},"Recensioni delle azioni","reviews","\u002Fblog\u002Fcategory\u002Freviews",[],{"id":183,"title":360,"date":361,"excerpt":362,"wordCount":363,"uri":364,"slug":365,"cloudinaryAssetId":366,"featuredImageOriginalUrl":367,"featuredImageMetadata":368,"author":369,"categories":371,"relatedPosts":373},"Rivian ha toccato un minimo annuale il giorno dopo l'acquisto di una startup di simulazione AI. Ecco cosa mostra il 29 ottobre","2026-10-26 07:50:00","Rivian ha toccato un minimo annuale il giorno dopo l'acquisizione di una startup di simulazione AI, prolungando un calo del 19% iniziato settimane prima. Il rapporto del 29 ottobre ora deve dimostrare che la linea dei costi può sostenere le spese per l'autonomia.",925,"\u002Fblog\u002Frivian-hit-a-52-week-low-the-day-after-buying-an-ai-simulation-startup-heres-what-october-29-has-to-show","rivian-hit-a-52-week-low-the-day-after-buying-an-ai-simulation-startup-heres-what-october-29-has-to-show","images\u002F12-10_145310df477\u002F12-10_145310df477","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976166\u002Fimages\u002F12-10_145310df477\u002F12-10_145310df477.png?_i=AA",{"altText":360},{"name":350,"slug":351,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":370},[],[372],{"name":355,"slug":356,"uri":357,"description":171,"postsCount":183},[],{"id":183,"title":375,"date":376,"excerpt":377,"wordCount":378,"uri":379,"slug":380,"cloudinaryAssetId":381,"featuredImageOriginalUrl":382,"featuredImageMetadata":383,"author":384,"categories":386,"relatedPosts":388},"Il titolo Robinhood è sceso del 15% a ottobre prima del suo rapporto sul terzo trimestre. Ecco dove potrebbe arrivare entro il 2030","2026-10-26 07:45:00","Robinhood è sceso del 6,73% in due sedute, in linea con Coinbase, prima del suo report del 27 ottobre. Due sviluppi del 22 ottobre indicano un'attività crypto che potrebbe non riflettersi nella sua linea di ricavi crypto: contratti sul prezzo del bitcoin e i primi mercati di prestito di Morpho per i suoi token azionari.",854,"\u002Fblog\u002Frobinhood-stock-fell-15-in-october-before-its-q3-report-heres-where-it-could-go-by-2030","robinhood-stock-fell-15-in-october-before-its-q3-report-heres-where-it-could-go-by-2030","images\u002F11-11_145309e717b\u002F11-11_145309e717b","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976143\u002Fimages\u002F11-11_145309e717b\u002F11-11_145309e717b.png?_i=AA",{"altText":375},{"name":350,"slug":351,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":385},[],[387],{"name":355,"slug":356,"uri":357,"description":171,"postsCount":183},[],{"id":183,"title":390,"date":391,"excerpt":392,"wordCount":393,"uri":394,"slug":395,"cloudinaryAssetId":396,"featuredImageOriginalUrl":397,"featuredImageMetadata":398,"author":399,"categories":401,"relatedPosts":403},"Le Azioni di Walmart Sono Salite del 15% a Ottobre Senza Previsioni di Utili Più Alte. Ecco Dove Potrebbero Andare Entro il 2031","2026-10-26 07:40:00","Walmart è salito del 15,4% dal 30 settembre al 23 ottobre, ma la stima degli analisti per l'EPS dei prossimi 12 mesi è rimasta a 3,00 dollari per azione. Quasi tutto il guadagno è derivato da un multiplo più elevato, in vista di un rapporto del 19 novembre che prevede una crescita dell'EPS compresa tra lo 0% e il 3%.",832,"\u002Fblog\u002Fwalmart-stock-rose-15-in-october-without-a-higher-earnings-forecast-heres-where-it-could-go-by-2031","walmart-stock-rose-15-in-october-without-a-higher-earnings-forecast-heres-where-it-could-go-by-2031","images\u002F10-14_145308a5c00\u002F10-14_145308a5c00","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976123\u002Fimages\u002F10-14_145308a5c00\u002F10-14_145308a5c00.png?_i=AA",{"altText":390},{"name":350,"slug":351,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":400},[],[402],{"name":355,"slug":356,"uri":357,"description":171,"postsCount":183},[],{"id":183,"title":405,"date":406,"excerpt":407,"wordCount":408,"uri":409,"slug":410,"cloudinaryAssetId":411,"featuredImageOriginalUrl":412,"featuredImageMetadata":413,"author":414,"categories":416,"relatedPosts":418},"Apple ha brevemente superato Nvidia mentre il calo di Nvidia raggiungeva il 12%. Ecco dove potrebbe arrivare il titolo Apple entro il 2030","2026-10-26 07:35:00","Apple ha brevemente superato Nvidia come azienda più preziosa al mondo il 23 ottobre, toccando un record di $351,73. La sua strategia di IA richiede poco capex, ma a 38 volte gli utili, il dato sui margini del 2 novembre sostiene il multiplo.",845,"\u002Fblog\u002Fapple-briefly-topped-nvidia-as-nvidias-slide-reached-12-heres-where-apple-stock-could-go-by-2030","apple-briefly-topped-nvidia-as-nvidias-slide-reached-12-heres-where-apple-stock-could-go-by-2030","images\u002F9-15_1453077213e\u002F9-15_1453077213e","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792976106\u002Fimages\u002F9-15_1453077213e\u002F9-15_1453077213e.png?_i=AA",{"altText":405},{"name":350,"slug":351,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":415},[],[417],{"name":355,"slug":356,"uri":357,"description":171,"postsCount":183},[]]